Analyzing Klotho Neurosciences (KLTO) and Its Peers

Institutional and Insider Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.7% of Klotho Neurosciences shares are owned by insiders. Comparatively, 15.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Klotho Neurosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	N/A	-25.89%
Klotho Neurosciences Competitors	-2,185.76%	-161.46%	-40.62%

Risk and Volatility

Klotho Neurosciences has a beta of -1.1, meaning that its share price is 210% less volatile than the S&P 500. Comparatively, Klotho Neurosciences’ competitors have a beta of -4.57, meaning that their average share price is 557% less volatile than the S&P 500.

Valuation & Earnings

This table compares Klotho Neurosciences and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Klotho Neurosciences	N/A	$1.35 million	-0.49
Klotho Neurosciences Competitors	$581.03 million	-$70.44 million	3.60

Klotho Neurosciences’ competitors have higher revenue, but lower earnings than Klotho Neurosciences. Klotho Neurosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Klotho Neurosciences beats its competitors on 6 of the 9 factors compared.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.